Kamiński Karol A, Winnicka Maria M, Zdunek Inga, Musiał Włodzimierz J
Klinika Kardiologii Akademii Medycznej w Białymstoku.
Przegl Lek. 2007;64(1):48-53.
Coronary heart disease remains one of the main problems in healthcare systems in western countries. Despite a vast improvement in revascularisation techniques in recent years, we still encounter many patients, who are not suitable for conventional revasularisation methods. A delivery of proangiogenic substances like VEGF or FGF to cardiac muscle was thought to help these patients. Nevertheless, in order to induce angiogenesis in heart in safe and efficient manner further studies of mechanism regulating vessel growth are necessary. This interest resulted in still increasing number of papers dealing with angiogenesis in heart. Still, the results of clinical studies were in large part discouraging. Therefore novel angiogenic substances are currently under investigation. The great expectations are associated with proteins affecting multiple levels and processes involved in vessel growth and maturation. These include among others PIGF and CYR61. Other promising approach is the induction of angiogenesis by stem cells and endothelial progenitor cells. Hopefully these efforts will soon reveal therapeutic methods, which will be applicable in patients with severe ischemic heart disease disqualified from conventional revascularisation procedures.
冠心病仍然是西方国家医疗保健系统中的主要问题之一。尽管近年来血管重建技术有了巨大进步,但我们仍会遇到许多不适合传统血管重建方法的患者。向心肌递送血管生成物质如VEGF或FGF被认为有助于这些患者。然而,为了以安全有效的方式诱导心脏血管生成,有必要进一步研究调节血管生长的机制。这种兴趣导致研究心脏血管生成的论文数量不断增加。尽管如此,临床研究结果在很大程度上令人沮丧。因此,目前正在研究新型血管生成物质。人们对影响血管生长和成熟的多个层面和过程的蛋白质寄予厚望。其中包括胎盘生长因子(PIGF)和富含半胱氨酸的血管生成素(CYR61)。另一种有前景的方法是通过干细胞和内皮祖细胞诱导血管生成。有望这些努力很快能揭示出适用于因传统血管重建手术不合格而患有严重缺血性心脏病患者的治疗方法。